201 related articles for article (PubMed ID: 31283840)
21. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type.
Raderer M; Traub T; Formanek M; Virgolini I; Osterreicher C; Fiebiger W; Penz M; Jäger U; Pont J; Chott A; Kurtaran A
Br J Cancer; 2001 Nov; 85(10):1462-6. PubMed ID: 11720429
[TBL] [Abstract][Full Text] [Related]
22. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
24. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
25. Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
Kiesewetter B; Simonitsch-Klupp I; Dolak W; Mayerhoefer ME; Raderer M
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093228
[TBL] [Abstract][Full Text] [Related]
26. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
[TBL] [Abstract][Full Text] [Related]
27. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
[TBL] [Abstract][Full Text] [Related]
28. Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.
Kiesewetter B; Ferreri AJ; Raderer M
Oncologist; 2015 Aug; 20(8):915-25. PubMed ID: 26156327
[TBL] [Abstract][Full Text] [Related]
29. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy.
Wenzel C; Fiebiger W; Dieckmann K; Formanek M; Chott A; Raderer M
Cancer; 2003 May; 97(9):2236-41. PubMed ID: 12712477
[TBL] [Abstract][Full Text] [Related]
30. Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna.
Pokorny A; Kiesewetter B; Raderer M
Hematol Oncol; 2020 Aug; 38(3):409-411. PubMed ID: 32347560
[No Abstract] [Full Text] [Related]
31. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
34. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
Kiesewetter B; Raderer M
Hematol Oncol; 2020 Oct; 38(4):417-424. PubMed ID: 32469432
[TBL] [Abstract][Full Text] [Related]
36. Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease.
Raderer M; Püspök A; Stummvoll G; Längle F; Chott A
Scand J Gastroenterol; 2003 Mar; 38(3):294-7. PubMed ID: 12737445
[TBL] [Abstract][Full Text] [Related]
37. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
[TBL] [Abstract][Full Text] [Related]
38. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
[TBL] [Abstract][Full Text] [Related]
39. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
40. A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy.
Abe S; Oda I; Inaba K; Suzuki H; Yoshinaga S; Nonaka S; Morota M; Murakami N; Itami J; Kobayashi Y; Maeshima AM; Saito Y
Jpn J Clin Oncol; 2013 Sep; 43(9):917-22. PubMed ID: 23878345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
